Meeting
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
Authors
Wen Zhang
Department of medical oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Wen Zhang , Haitao Zhou , Jun Jiang , Yuelu Zhu , Shuangmei Zou , Yuan Tang , Jianwei Liang , Yongkun SUN , Zhichao Jiang , Zhixiang Zhou , Aiping Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03443661
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 69)
DOI
10.1200/JCO.2021.39.3_suppl.69
Abstract #
69
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of CAPOXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSGO).
First Author: Yoshinori Kagawa
Poster
2020 Gastrointestinal Cancers Symposium
The comparison of mFOLFOXIRI with CAOX/SOX as neoadjuvant chemotherapy for locally advanced rectal cancer.
First Author: Tetsuji Terazawa
Poster
2016 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy alone with mFOLFOXIRI in locally advanced rectal cancer: A single-arm phase II study.
First Author: Yanhong Deng